Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Reiss

Showing results (221-230 of 509) with videos related to

Pageof 51
Sort By:
The Journal of Infectious Diseases|September 22, 2017
Higher Prevalence and Faster Progression of Chronic Kidney Disease in Human Immunodeficiency Virus-Infected Middle-Aged Individuals Compared With Human Immunodeficiency Virus-Uninfected ControlsKatherine W Kooij, Liffert Vogt, Ferdinand W N M Wit, et al.
Nanoscale Advances|September 22, 2022
Long-term ambient air-stable cubic CsPbBr<sub>3</sub> perovskite quantum dots using molecular bromineSurakcha Thapa, Karishma Bhardwaj, Siddhant Basel, et al.
Journal of Neurovirology|December 7, 2021
Correlation between cerebrospinal fluid and plasma neurofilament light protein in treated HIV infection: results from the COBRA studyJasmini Alagaratnam, Davide De Francesco, Henrik Zetterberg, et al.
AIDS (London, England)|August 28, 2007
Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-scoreAmanda Mocroft, Bruno Ledergerber, Kai Zilmer, et al.
AIDS (London, England)|December 24, 2013
Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive personsLene Ryom, Amanda Mocroft, Ole Kirk, et al.
Plos One|February 8, 2023
Characteristics and short- and long-term direct medical costs among adults with timely and delayed presentation for HIV care in the NetherlandsStephanie Popping, Lisbeth Versteegh, Brooke E Nichols, et al.
Current Opinion in HIV and AIDS|October 8, 2019
Is reaching 90-90-90 enough to end AIDS? Lessons from AmsterdamGodelieve J de Bree, Ard van Sighem, Wim Zuilhof, et al.
Antiviral Therapy|October 2, 2003
Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavirRob E Aarnoutse, Jan-Christian Wasmuth, Gerd Fätkenheuer, et al.
Nanoscale Advances|September 22, 2022
Stable lead-halide perovskite quantum dots as efficient visible light photocatalysts for organic transformationsSajan Pradhan, Deshaj Bhujel, Bikram Gurung, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 7, 2007
CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greaterLuuk Gras, Anouk M Kesselring, James T Griffin, et al.
Pageof 51

Showing results (221-230 of 509) with videos related to

Sort By:
Pageof 51
The Journal of Infectious Diseases|September 22, 2017
Higher Prevalence and Faster Progression of Chronic Kidney Disease in Human Immunodeficiency Virus-Infected Middle-Aged Individuals Compared With Human Immunodeficiency Virus-Uninfected ControlsKatherine W Kooij, Liffert Vogt, Ferdinand W N M Wit, et al.
Nanoscale Advances|September 22, 2022
Long-term ambient air-stable cubic CsPbBr<sub>3</sub> perovskite quantum dots using molecular bromineSurakcha Thapa, Karishma Bhardwaj, Siddhant Basel, et al.
Journal of Neurovirology|December 7, 2021
Correlation between cerebrospinal fluid and plasma neurofilament light protein in treated HIV infection: results from the COBRA studyJasmini Alagaratnam, Davide De Francesco, Henrik Zetterberg, et al.
AIDS (London, England)|August 28, 2007
Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-scoreAmanda Mocroft, Bruno Ledergerber, Kai Zilmer, et al.
AIDS (London, England)|December 24, 2013
Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive personsLene Ryom, Amanda Mocroft, Ole Kirk, et al.
Plos One|February 8, 2023
Characteristics and short- and long-term direct medical costs among adults with timely and delayed presentation for HIV care in the NetherlandsStephanie Popping, Lisbeth Versteegh, Brooke E Nichols, et al.
Current Opinion in HIV and AIDS|October 8, 2019
Is reaching 90-90-90 enough to end AIDS? Lessons from AmsterdamGodelieve J de Bree, Ard van Sighem, Wim Zuilhof, et al.
Antiviral Therapy|October 2, 2003
Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavirRob E Aarnoutse, Jan-Christian Wasmuth, Gerd Fätkenheuer, et al.
Nanoscale Advances|September 22, 2022
Stable lead-halide perovskite quantum dots as efficient visible light photocatalysts for organic transformationsSajan Pradhan, Deshaj Bhujel, Bikram Gurung, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 7, 2007
CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greaterLuuk Gras, Anouk M Kesselring, James T Griffin, et al.
Pageof 51